Tandem Diabetes Care Beheer
Beheer criteriumcontroles 4/4
De CEO Tandem Diabetes Care is John Sheridan, benoemd in Apr2013, heeft een ambtstermijn van 11.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.65M, bestaande uit 15.3% salaris en 84.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.083% van de aandelen van het bedrijf, ter waarde $ 1.67M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 4.3 jaar.
Belangrijke informatie
John Sheridan
Algemeen directeur
US$4.7m
Totale compensatie
| Percentage CEO-salaris | 15.3% |
| Dienstverband CEO | 11.6yrs |
| Eigendom CEO | 0.08% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch
Nov 16
Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?
Sep 28Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk
Aug 31Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
Aug 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 04Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Jul 12Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Jun 18Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
May 29Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors
May 10A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
May 04At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
Mar 26Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
Mar 08Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Feb 22Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jan 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company
Dec 27Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Nov 12Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price
Oct 06Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Sep 17Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?
Aug 08Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jul 03Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?
Jun 13Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
May 06Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Jan 04Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?
Oct 15Tandem Diabetes Care: Overpriced, Underdelivering
Sep 22An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued
Sep 10Tandem Diabetes stock falls 10% on disappointing Q2 result
Aug 03Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed
Jul 21Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings
Jul 08Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital
Jun 20Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price
May 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$127m |
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$141m |
| Dec 31 2023 | US$5m | US$711k | -US$223m |
| Sep 30 2023 | n/a | n/a | -US$208m |
| Jun 30 2023 | n/a | n/a | -US$224m |
| Mar 31 2023 | n/a | n/a | -US$204m |
| Dec 31 2022 | US$6m | US$711k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$68m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | US$6m |
| Dec 31 2021 | US$6m | US$690k | US$16m |
| Sep 30 2021 | n/a | n/a | US$22m |
| Jun 30 2021 | n/a | n/a | US$7m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$4m | US$600k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$49m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$11m | US$500k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$113m |
| Dec 31 2018 | US$2m | US$386k | -US$123m |
| Sep 30 2018 | n/a | n/a | -US$138m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$82m |
| Dec 31 2017 | US$596k | US$375k | -US$73m |
Compensatie versus markt: De totale vergoeding ($USD 4.65M ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.43M ).
Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
John Sheridan (69 yo)
11.6yrs
Tenure
US$4,651,603
Compensatie
Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 11.6yrs | US$4.65m | 0.083% $ 1.7m | |
| Executive VP | 6.8yrs | US$1.25m | 0.051% $ 1.0m | |
| Executive VP & Chief Administrative Officer | 11.2yrs | US$1.25m | 0.038% $ 765.4k | |
| Transitional Advisor | less than a year | US$1.25m | 0.011% $ 214.6k | |
| Executive Vice President and Chief Strategy & Product Officer | 3.4yrs | US$1.25m | 0.022% $ 453.0k | |
| Executive VP & Chief Commercial Officer | less than a year | US$2.72m | 0.00081% $ 16.4k | |
| Executive VP & COO | less than a year | geen gegevens | geen gegevens | |
| Chief Technical Officer | 3yrs | geen gegevens | 0.022% $ 451.0k | |
| Executive VP | 2.8yrs | geen gegevens | 0.020% $ 413.1k | |
| Chief Human Resources Officer | 7.3yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Manufacturing Officer | 7.3yrs | geen gegevens | 0.026% $ 518.9k |
3.2yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TNDM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.4yrs | US$4.65m | 0.083% $ 1.7m | |
| Independent Chairwoman of the Board | 5.8yrs | US$222.78k | 0.014% $ 288.9k | |
| Chair Emeritus | less than a year | US$198.78k | 0.34% $ 6.9m | |
| Independent Director | 11.3yrs | US$200.95k | 0.036% $ 736.7k | |
| Independent Director | 17.3yrs | US$214.67k | 0.059% $ 1.2m | |
| Independent Director | 4.3yrs | US$190.28k | 0.025% $ 513.0k | |
| Independent Director | 3.8yrs | US$189.25k | 0.017% $ 342.2k | |
| Independent Director | 4.4yrs | US$189.25k | 0.021% $ 413.9k | |
| Independent Director | 2.4yrs | US$176.55k | 0.012% $ 232.6k | |
| Independent Director | 2.4yrs | US$177.55k | 0.012% $ 232.6k |
4.3yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TNDM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).